Liver Transplantation for Budd-Chiari Syndrome From Myeloproliferative Neoplasms - Management and Long-Term Results.

Autor: Tekbaş A; Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University, Jena, Germany; Research Programme 'Advanced Clinician Scientist Programme' by the Interdisciplinary Center of Clinical Research of the Medical Faculty Jena, Jena University Hospital, Friedrich Schiller University, Jena, Germany. Electronic address: Aysun.Tekbas@med.uni-jena.de., Schilling K; Department of Hematology and Medical Oncology, Jena University Hospital, Friedrich Schiller University, Jena, Germany., Fahrner R; Spital Thun, Department of General and Visceral Surgery, Thun, Switzerland., Morath O; Department of Hematology and Medical Oncology, Jena University Hospital, Friedrich Schiller University, Jena, Germany; Research Programme 'DFG Clinician Scientist Programme Organ Age' by the Interdisciplinary Center of Clinical Research of the Medical Faculty Jena, Jena University Hospital, Friedrich Schiller University, Jena, Germany., Malessa C; Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University, Jena, Germany., Bauschke A; Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University, Jena, Germany., Settmacher U; Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University, Jena, Germany., Rauchfuß F; Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Jazyk: angličtina
Zdroj: Transplantation proceedings [Transplant Proc] 2024 Oct; Vol. 56 (8), pp. 1759-1765. Date of Electronic Publication: 2024 Sep 05.
DOI: 10.1016/j.transproceed.2024.08.040
Abstrakt: Myeloproliferative neoplasms can cause primary Budd-Chiari-Syndrome with acute or chronic liver failure necessitating liver transplantation. However, preventing the recurrence remains challenging and the need for post-transplant anticoagulant and cytoreductive treatment is not sufficiently clear. We analyzed the treatment regimens for all patients who presented to our department with PBCS from MPN between 2004 and 2021. Eight patients underwent liver transplantation - 6 of them due to an acute liver failure. Post-transplant, all patients received anticoagulant and 7 patients cytoreductive medication. The mean survival after transplantation was 13.25 years. Liver transplantation shows favorable long-term outcome when combined with post-transplant anticoagulant and cytoreductive treatment.
Competing Interests: Declaration of competing interest The author Aysun Tekbaș and the coauthor Olga Morath receive fundings from the Interdisciplinary Center of Clinical Research of the Medical Faculty Jena, Germany.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: